Tellus Therapeutics, Inc. Company Profile

Background

Tellus Therapeutics, Inc., founded in 2018, is a biopharmaceutical company dedicated to developing safe and effective treatments for unmet needs in newborns. The company's mission is to provide therapeutic interventions that improve neurodevelopmental outcomes for infants at risk of brain injuries, particularly those born prematurely.

Key Strategic Focus

Tellus Therapeutics focuses on addressing neonatal brain injuries, with a primary emphasis on diffuse white matter injury (DWMI) in preterm infants. The company's lead candidate, TT-20, is derived from compounds found in human breast milk that promote myelination and repair white matter damage. By targeting the underlying mechanisms of myelin injury, Tellus aims to develop treatments that can reverse motor deficits and improve cognitive functions in affected newborns.

Financials and Funding

Tellus Therapeutics has secured significant funding to advance its research and development efforts:

Seed Financing (May 2021): The company received an undisclosed seed investment from Xontogeny, LLC, to support the advancement of TT-20 through IND-enabling studies.

Series A Financing (December 2022): Tellus raised $35 million in a Series A funding round led by Perceptive Xontogeny Venture Fund. The funds are intended to support the development of TT-20 into clinical trials and to expand the company's pipeline program.

Pipeline Development

Tellus Therapeutics' lead candidate, TT-20, is in late preclinical development for the treatment of DWMI in preterm infants. The company is pursuing a "First-in-Neonate" regulatory pathway to evaluate the safety and efficacy of TT-20 in newborns with brain injuries. Additionally, Tellus is developing a pipeline targeting other neonatal unmet needs, leveraging its expertise in neonatal drug development.

Technological Platform and Innovation

Tellus Therapeutics' innovative approach centers on translating breakthrough science from Dr. Eric Benner's laboratory at Duke University. The company's proprietary technology involves small molecules derived from human breast milk that promote oligodendrocyte differentiation and myelination. This reparative mechanism is independent of the cause of white matter injury, offering a potential advantage over neuroprotective approaches that focus solely on injury prevention.

Leadership Team

Jason Kralic, Ph.D. – Co-Founder, Chief Executive Officer & Board Member: Dr. Kralic is a neuropharmacologist and life sciences business development executive with extensive experience in technology innovation and neurology/psychiatry R&D. He has held leadership roles at GlaxoSmithKline, Wake Forest Baptist Medical Center, Opexa Therapeutics, UCB Pharma, and Schwarz Biosciences.

Eric Benner, M.D., Ph.D. – Co-Founder, Acting Chief Scientific Officer & Board Member: Dr. Benner is a board-certified neonatologist at Duke University with over a decade of experience caring for neonates with brain injuries. His research identified compounds in breast milk that promote myelination, forming the basis for Tellus' lead program.

Austin Schwartz, Ph.D., MBA – Vice President of Operations and Finance: Dr. Schwartz is a life science operations professional with a background bridging science and business. He manages program development, company finances, corporate strategy, fundraising, and intellectual property management at Tellus.

Jaron Ballentine, MBA – Vice President of Clinical Operations and Business Development: Mr. Ballentine has experience in developing new life science products, with a background in commercial strategy and business analytics at GlaxoSmithKline. He has also managed his own consulting firm, partnering with life science companies on commercial and clinical strategies.

Leadership Changes

In May 2021, Tellus Therapeutics announced the appointment of Chris Garabedian, CEO of Xontogeny, as Chairman of the Board, and Fred Callori, Senior Vice President of Corporate Development at Xontogeny, as a Board Member. These appointments followed Xontogeny's seed investment in Tellus, reflecting a strategic partnership to advance the company's development programs.

Competitor Profile

Market Insights and Dynamics

The neonatal therapeutics market is characterized by a high unmet need for effective treatments addressing neonatal brain injuries, particularly DWMI in preterm infants. The absence of FDA-approved therapies in this area presents significant opportunities for innovation and development.

Competitor Analysis

While specific competitors focusing on neonatal white matter injury are limited, companies engaged in neonatal and pediatric neurology therapeutics include:

Novoron Bioscience: Focuses on developing therapies for central nervous system injuries and demyelinating diseases.

Rebiotix: Specializes in microbiome-based therapeutics, including treatments for pediatric conditions.

Enterome: Develops immunomodulatory drugs targeting microbiome-associated diseases, including pediatric indications.

CosmosID: Provides microbiome analysis services that can support neonatal and pediatric research.

Barinthus Biotherapeutics: Engages in developing biotherapeutics for various indications, including pediatric applications.

Strategic Collaborations and Partnerships

Tellus Therapeutics has established key partnerships to support its development programs:

Xontogeny, LLC: Provided seed investment and strategic guidance to advance TT-20 through IND-enabling studies.

Perceptive Xontogeny Venture Fund: Led the $35 million Series A financing to support clinical trials and pipeline expansion.

Duke University: The company's foundational science is licensed from research conducted at Duke University, particularly from Dr. Eric Benner's laboratory.

Operational Insights

Tellus Therapeutics' strategic focus on neonatal brain injuries positions it uniquely in a market with limited competition. The company's proprietary technology, derived from human breast milk compounds, offers a novel approach to treating DWMI. Strategic partnerships with Xontogeny and Perceptive Xontogeny Venture Fund provide financial support and industry expertise, enhancing Tellus' capacity to navigate the complex regulatory and developmental pathways in neonatal therapeutics.

Strategic Opportunities and Future Directions

Tellus Therapeutics aims to advance TT-20 into clinical trials, targeting a "First-in-Neonate" regulatory pathway to evaluate its safety and efficacy in newborns with brain injuries. The company is also expanding its pipeline to address other neonatal unmet needs, leveraging its expertise in neonatal drug development. Continued collaboration with strategic partners and regulatory agencies will be crucial in achieving these objectives and bringing innovative therapies to market for vulnerable neonatal populations.